Novofen (Tamoxifen)

Tamoxifen, the active ingredient in Novofen, is a selective estrogen receptor modulator presented as a 20 mg tablet for oral use. It is employed in hormone‑responsive breast cancer treatment and prevention in adult women and men. GNH USA supplies Novofen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Novofen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Tamoxifen is a selective estrogen receptor modulator used in conditions that involve estrogen‑driven pathology.

- Early‑stage hormone‑responsive breast cancer: improves survival by reducing recurrence risk. - Metastatic breast cancer: helps control disease progression. - Male breast cancer: provides anti‑estrogen effects similar to those in women. - Ductal carcinoma in situ (DCIS): lowers the chance of invasive cancer development. - High‑risk women (e.g., BRCA‑positive): lowers the incidence of breast cancer. - Gynecologic benign conditions such as uterine fibroids (off‑label use, noted in clinical practice).

Side effects vary with dose and treatment duration, and are monitored throughout therapy.

Common Side Effects: - Hot‑spots and flush sensation of the skin (hot flashes). - Nausea or mild gastrointestinal upset. - Fatigue or general tiredness. - Vaginal dryness or discharge. - Mild weight gain. - Mood changes, including mild depression.

Serious or Rare Side Effects: - Deep‑vein thrombosis or pulmonary embolism. - Endometrial hyperplasia or carcinoma. - Severe liver enzyme elevation. - Visual disturbances or retinal toxicity. - Severe allergic reactions (anaphylaxis). - Significant neutropenia or pancytopenia.

Patients should be evaluated for risk factors and monitored regularly while on Tamoxifen.

- Baseline assessment: obtain medical history, especially thrombotic or uterine conditions. - Monitor liver function: periodic liver enzyme tests are recommended. - Gynecologic surveillance: regular pelvic exams and ultrasound for endometrial changes. - Pregnancy avoidance: use effective contraception during treatment and for several months after cessation. - Drug‑interaction review: assess concomitant medications that affect coagulation or CYP2D6 metabolism. - Store at below 20°C: keep tablets in the original container, protect from moisture and direct sunlight.

Tamoxifen may interact with several medicines that alter its metabolism or increase clotting risk.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) – reduce tamoxifen activation. - Anticoagulants (warfarin) – heightened bleeding risk. - Hormonal contraceptives containing estrogen – may increase thrombotic risk.

Moderate Interaction Molecules : - SSRIs/SNRIs (other than strong CYP2D6 inhibitors) – monitor for additive side‑effects. - Antifungal agents (e.g., ketoconazole) – may raise tamoxifen levels. - St. John Wick (???)  ");